Search results for "VASCULAR RISK"

showing 10 items of 328 documents

A Combined Multidisciplinary Intervention for Health Promotion in the Workplace: A Pilot Study

2021

The aim of this study was to assess the effects of a joint health promotion intervention on a cohort of healthcare workers (HCWs) who had at least one cardiovascular risk factor. The HCWs were assessed at three different times, i.e., time zero (T0), after 6 months (T6), and after 12 months (T12). The following parameters were measured at a medical examination: physical activity, blood pressure, waist circumference, body mass index (BMI), routine laboratory tests, plicometric analysis, work ability index (WAI), and body image dissatisfaction (BID). Among the 447 HCWs, 38 HCWs were included in the study; 45% (n = 17) were male. At T12, the average blood pressure, waist/hip ratio (WHR) index, …

medicine.medical_specialtyWaistMediterranean diethealth care facilities manpower and serviceseducationlcsh:Medicine030209 endocrinology & metabolismArticle03 medical and health sciences0302 clinical medicineWorkplace health promotionMediterranean dietHealth careMedicinecardiovascular risk factorbody image dissatisfaction (BID)030212 general & internal medicineRisk factorbusiness.industryhealthcare workerslcsh:Rvirus diseasesGeneral Medicinework ability index (WAI)Health promotionworkplace health promotion; healthcare workers; cardiovascular risk factor; work ability index (WAI); Mediterranean diet; body image dissatisfaction (BID)CohortHealthcare workerPhysical therapyworkplace health promotionbusinessBody mass indexJournal of Clinical Medicine
researchProduct

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardio…

2013

1. INTRODUCTION1.1 PrinciplesThe 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines continue to adhere to some fundamental principles that inspired the 2003 and 2007 guidelines, namely to base recommendations on properly conducted studies identified from an ext

medicine.medical_specialtyArterieKidney DiseasePrognosiPhysiologyCardiologyBlood PressureGuidelineRisk AssessmentDevice therapyRisk FactorsInternal medicineAntihypertensive treatmentInternal MedicineMedicineHumansIntensive care medicineLife StyleAntihypertensive Agentsbusiness.industryTask forceRisk FactorCardiovascular complicationOrgan damageArteriesCardiovascular riskLifestylePrognosisOrgan damageDevice therapyAntihypertensive AgentBlood pressureHypertensionCardiologyKidney DiseasesbusinessCardiology and Cardiovascular MedicineHumanJournal of hypertension
researchProduct

Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study

2021

The Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension conceived and designed an ad hoc study aimed at searching for prognostic cut-off values of serum uric acid (SUA) in predicting combined (fatal and non-fatal) cerebrovascular (CBV) events in the whole database. The URic acid Right for heArt Health study is a nationwide, multicenter, observational cohort study involving data on subjects aged 18-95 years recruited on a regional community basis from all the territory of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 120.7 ± 61.8 months. A total of 14,588 subjects were included in the analysis. A prognos…

medicine.medical_specialtySettore MED/09 - Medicina Internauric acid cardiovascular riskserum uric acid; stroke; hypertension; cardiovascular prevention; cardiovascular diseasechemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansStrokeuric acid hypertensionbusiness.industryConfoundingPrognosismedicine.diseaseConfidence intervalUric AcidStrokechemistryHypertensionUric acidbusinessBody mass indexCohort studyKidney disease
researchProduct

Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.

2011

Objective To quantify the magnitude and pattern of low-density lipoprotein (LDL) cholesterol and nonhigh-density lipoprotein (HDL) cholesterol levels in women with polycystic ovary syndrome (PCOS) versus control women. Design Systematic review and meta-analysis of lipid levels in published cross-sectional studies worldwide where PCOS women and controls were examined and sampled. Main Outcome Measure(s) Differences in plasma lipids (including triglycerides, HDL-cholesterol, LDL-cholesterol, and nonHDL-cholesterol) in PCOS versus control subjects were calculated. Comparisons were made with and without body mass index (BMI) matching. Result(s) Triglyceride levels were 26 mg/dL (95% confidence …

medicine.medical_specialtySettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundRisk FactorsMedicineHumansDyslipidemiasGynecologyTriglyceridebusiness.industryCholesterolHyperandrogenismnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryLipidsConfidence intervalReproductive MedicinechemistryPolycystic Ovary Syndrome dyslipidemia cardiovascular risklipids (amino acids peptides and proteins)FemalebusinessHyperandrogenismBody mass indexDyslipidemiaLipoproteinPolycystic Ovary SyndromeFertility and sterility
researchProduct

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia.

2010

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitative changes in LDL, with small net effects on atherogenic dyslipidaemia. This is supported by findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression, where the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolaemia did not affect the mean change in carotid int…

cardiovascular riskAortic valvemedicine.medical_specialtydyslipidaemiamedicine.drug_classezetimibe cardiovascular risk atherosclerosis dyslipidaemiachemistry.chemical_compoundEzetimibeInternal medicineClinical endpointMedicineCholesterol absorption inhibitorcardiovascular diseasesReview Paperbusiness.industryCholesterolnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStenosismedicine.anatomical_structureEndocrinologychemistrySimvastatinCardiologylipids (amino acids peptides and proteins)atherosclerosisbusinessezetimibeLipoproteinmedicine.drug
researchProduct

Periodontitis, blood lipids and lipoproteins

2014

Periodontitis, one of the most common chronic infections in adults, is characterized by the accumulation of dental plaque and infection by gram-negative pathogens bacteria, which further lead to the destruction of periodontal tissues. A relationship between chronic periodontitis and abnormalities in lipid and/or lipoprotein metabolism is not well understood yet. Periodontitis is associated with elevated pro-atherogenic plasma-lipids, including small dense LDL, while oxidized LDL may act as inflammatory stimulant in periodontitis. Periodontal pathogens may directly modify lipoprotein, including protective characteristics of HDL and contribute to development of metabolic syndrome, Type 2 diab…

Periodontitismedicine.medical_specialtybiologybusiness.industryEndocrinology Diabetes and MetabolismType 2 Diabetes MellitusBlood lipidsmedicine.diseasebiology.organism_classificationDental plaqueChronic periodontitiscardiovascular risk inflammation lipids lipoproteins periodontitis sdLDLchemistry.chemical_compoundEndocrinologychemistryLow-density lipoproteinInternal medicineImmunologymedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPorphyromonas gingivalisLipoproteinClinical Lipidology
researchProduct

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collabora…

2018

PubMed: 30270054

International CooperationMÉTODOS EPIDEMIOLÓGICOS030204 cardiovascular system & hematologyNationwide surveyGlobal HealthHealth Services AccessibilityDoenças Cardio e Cérebro-vascularesMOLECULAR-GENETICS0302 clinical medicineRisk FactorsPrevalenceCARDIOVASCULAR RISK-FACTORS030212 general & internal medicineCooperative BehaviorDEFECTIVE APOLIPOPROTEIN B-100GENERAL-POPULATIONeducation.field_of_studymedicine.diagnostic_testAnticholesteremic AgentsFamilial hypercholesterolaemia; FHSC; Primary dyslipidaemia; Anticholesteremic Agents; Biomarkers; Cholesterol LDL; Cooperative Behavior; Genetic Predisposition to Disease; Health Care Surveys; Health Services Accessibility; Healthcare Disparities; Humans; Hyperlipoproteinemia Type II; Phenotype; Predictive Value of Tests; Prevalence; Risk Factors; Treatment Outcome; Blood Component Removal; Global Health; International CooperationEAS Familial Hypercholesterolaemia Studies Collaboration3. Good healthPREVALENCECholesterolPhenotypeTreatment OutcomeBlood Component RemovalCORONARY-ARTERY-DISEASENATIONWIDE SURVEYCardiology and Cardiovascular MedicineFamilial hypercholesterolaemiamedicine.medical_specialtyCardiovascular risk factorsPopulationLDL-RECEPTOR1102 Cardiovascular Medicine And HaematologyLDLHyperlipoproteinemia Type II03 medical and health sciencesPredictive Value of TestsmedicineHumans:Medicine [Science]Genetic Predisposition to DiseasePrimary dyslipidaemiaHealthcare Disparitiesfhsc; familial hypercholesterolaemia; primary dyslipidaemiaeducationGenetic testingGovernmentPublic healthEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) InvestigatorsSAFEHEART REGISTRY1103 Clinical SciencesFHSCCholesterol LDLCardiovascular System & HematologyFamily medicineHealth Care Surveys3121 General medicine internal medicine and other clinical medicineCardiovascular System & CardiologyBusinessFOLLOW-UPBiomarkers
researchProduct

Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidis…

2020

High levels of LDL cholesterol (LDL-C) represent a causal factor for cardiovascular diseases on an atherosclerotic basis, with a direct correlation between these and mortality or cardiovascular events, such that the reduction of both is associated proportionally and linearly with the reduction of LDL-C.Statins and ezetimibe are used for LDL-C lowering but may not be sufficient to achieve the targets defined by the ESC/EAS guidelines, which recommend use of PCSK9 inhibitors for further LDL-C reduction in patients not at goal.This project submitted 86 clinical scenarios to a group of experts, cardiologists, internists and lipidologists, collecting their opinion on the appropriateness of diffe…

Settore MED/09 - Medicina InternaConsensusPCSK9 inhibitorFamilial hypercholesterolemiaHypercholesterolemiaAntibodies Monoclonal Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol LDL; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Risk Assessment; Risk Factors; Cardiovascular DiseasesConsensuAntibodies Monoclonal HumanizedRisk AssessmentAntibodiesLDLAcute coronary syndrome; Alirocumab; Cardiovascular risk; Familial hypercholesterolemia; PCSK9 inhibitors; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol LDL; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Risk Assessment; Risk Factors; Cardiovascular DiseasesRisk FactorsAnticholesteremic AgentMonoclonalHumansHumanizedAnticholesteremic AgentsCholesterol LDLCardiovascular riskAtherosclerosisCholesterolItalyPCSK9 inhibitorsCardiovascular DiseasesAtherosclerosiAcute coronary syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsAlirocumab
researchProduct

Influence of risk factors on nitric oxide metabolites at the initial stage of juvenile acute myocardial infarction.

2009

Few data are accessible about the nitric oxide (NO) stable end-products (nitrite/NO2 − and nitrate/NO3 − :N O x) in acute coronary syndromes. An increase in inducible NO synthase (iNOS) was found during experimental myocardial infarction [13] and this increase persisted for 2 weeks. In experimental models of acute myocardial infarction (AMI) other authors [2] observed a NOx increase, a correlation between NOx level and iNOS activity and an inhibitory action carried out by S-methylisothiourea, that is an iNOS inhibitor [5]. The NOx level was also measured in a small group of patients with myocardial infarction in whom the peak of NOx elevation occurred 2 and 3 days after the onset of symptom…

AdultMalemedicine.medical_specialtyPhysiologyMyocardial InfarctionNitric Oxide Synthase Type IIEssential hypertensionNitric OxideNitric oxideCoronary artery diseasechemistry.chemical_compoundYoung AdultGriess testRisk FactorsPhysiology (medical)Internal medicinemedicineJuvenile myocardial infarction cardiovascular risk factors nitrite nitrateHumansMyocardial infarctionNitriteNOxbusiness.industryHematologyVenous bloodMiddle Agedmedicine.diseaseSurgerychemistryCase-Control StudiesCardiologyFemaleCardiology and Cardiovascular MedicinebusinessClinical hemorheology and microcirculation
researchProduct

Absence of an independent association between serum uric acid and left ventricular mass in Caucasian hypertensive women and men

2013

Background and aim: Experimentally uric acid may induce cardiomyocyte growth and interstitial fibrosis of the heart. However, clinical studies exploring the relationship between serum uric acid (SUA) and left ventricular (LV) mass yielded conflicting results. The aim of our study was to evaluate the relationships between SUA and LV mass in a large group of Caucasian essential hypertensive subjects. Methods and results: We enrolled 534 hypertensive patients free of cardiovascular complications and without severe renal insufficiency. In all subjects routine blood chemistry, including SUA determination, echocardiographic examination and 24 h ambulatory blood pressure (BP) monitoring were obtai…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureEndocrinology Diabetes and MetabolismHeart VentriclesPopulationLeft ventricular maMedicine (miscellaneous)Blood PressureLeft ventricular hypertrophyEssential hypertensionWhite PeopleEssential hypertensionBody Mass Indexchemistry.chemical_compoundSerum uric acidInternal medicinemedicineHumansEssential hypertension; Serum uric acid; Cardiovascular risk; Left ventricular mass; Left ventricular hypertrophyeducationeducation.field_of_studyCreatinineNutrition and Dieteticsbusiness.industryLeft ventricular hypertrophyBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseCardiovascular riskUric AcidEndocrinologyBlood pressureCross-Sectional StudieschemistryBlood chemistryEchocardiographyCreatinineHypertensionCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct